[go: up one dir, main page]

MX2018015871A - Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc. - Google Patents

Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc.

Info

Publication number
MX2018015871A
MX2018015871A MX2018015871A MX2018015871A MX2018015871A MX 2018015871 A MX2018015871 A MX 2018015871A MX 2018015871 A MX2018015871 A MX 2018015871A MX 2018015871 A MX2018015871 A MX 2018015871A MX 2018015871 A MX2018015871 A MX 2018015871A
Authority
MX
Mexico
Prior art keywords
cenicriviroc
purified
intermediates
making
high purity
Prior art date
Application number
MX2018015871A
Other languages
English (en)
Inventor
Morra Nicholas
Phiasivongsa Pasit
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of MX2018015871A publication Critical patent/MX2018015871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • B01J31/2226—Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
    • B01J31/223—At least two oxygen atoms present in one at least bidentate or bridging ligand
    • B01J31/2239—Bridging ligands, e.g. OAc in Cr2(OAc)4, Pt4(OAc)8 or dicarboxylate ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
    • B01J2231/4205—C-C cross-coupling, e.g. metal catalyzed or Friedel-Crafts type
    • B01J2231/4211—Suzuki-type, i.e. RY + R'B(OR)2, in which R, R' are optionally substituted alkyl, alkenyl, aryl, acyl and Y is the leaving group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

Abstract

La descripción incluye compuestos de alta pureza que tienen antagonismo a CCR5 y/o CCR2, o sales de estos, intermedios pureza alta de estos y procesos para sintetizarlos.
MX2018015871A 2016-06-21 2017-06-21 Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc. MX2018015871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352885P 2016-06-21 2016-06-21
PCT/US2017/038460 WO2017223155A1 (en) 2016-06-21 2017-06-21 Purified cenicriviroc and purified intermediates for making cenicriviroc

Publications (1)

Publication Number Publication Date
MX2018015871A true MX2018015871A (es) 2019-08-14

Family

ID=60661588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015871A MX2018015871A (es) 2016-06-21 2017-06-21 Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc.

Country Status (13)

Country Link
US (3) US10407411B2 (es)
EP (1) EP3471718A4 (es)
JP (1) JP2019520427A (es)
KR (1) KR20190039087A (es)
CN (1) CN109862890A (es)
AU (1) AU2017280068A1 (es)
BR (1) BR112018076449A2 (es)
CA (1) CA3028151A1 (es)
IL (1) IL263789A (es)
MX (1) MX2018015871A (es)
RU (1) RU2019101242A (es)
SG (1) SG11201811140UA (es)
WO (1) WO2017223155A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
ATE199721T1 (de) 1994-07-04 2001-03-15 Takeda Chemical Industries Ltd Phosphonsäure verbindungen imre herstellung und verwendung
CN1282243A (zh) 1997-12-19 2001-01-31 武田药品工业株式会社 用于拮抗ccr5的含n－酰苯胺衍生物的药物组合物
CA2337307A1 (en) 1998-08-20 2000-03-02 Osamu Nishimura Quaternary ammonium salts and their use
WO2001017947A1 (en) 1999-09-06 2001-03-15 Takeda Chemical Industries, Ltd. Process for the preparation of 2,3-dihydroazepine compounds
ATE539062T1 (de) * 2001-08-08 2012-01-15 Tobira Therapeutics Inc Bizyklishe verbindung, ihre herstellung und verwendung
JP2004123694A (ja) * 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
US20080234343A1 (en) 2004-03-24 2008-09-25 Takeda Pharmaceutical Company Preparation with Elevated Content
WO2005089714A1 (ja) 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited エマルション安定化製剤
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
US20080031942A1 (en) 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
US7842696B2 (en) * 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
KR101639095B1 (ko) * 2009-01-23 2016-07-12 스미또모 가가꾸 가부시키가이샤 공역 방향족 화합물의 제조 방법
WO2012068366A2 (en) 2010-11-18 2012-05-24 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
MX383706B (es) 2013-05-15 2025-03-14 Tobira Therapeutics Inc Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
US20160095850A1 (en) * 2013-05-24 2016-04-07 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
BR112016021682A2 (pt) 2014-03-21 2018-06-26 Tobira Therapeutics, Inc. cenicriviroc para o tratamento da fibrose
RU2723559C2 (ru) * 2014-09-12 2020-06-16 Тобира Терапьютикс, Инк. Комбинированная терапия с применением препарата ценикривирок для лечения фиброза
US10526349B2 (en) 2014-12-23 2020-01-07 Tobira Therapeutics, Inc. Process of making cenicriviroc and related analogs
AU2015382376B2 (en) 2015-02-10 2021-07-01 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis

Also Published As

Publication number Publication date
CN109862890A (zh) 2019-06-07
SG11201811140UA (en) 2019-01-30
US10407411B2 (en) 2019-09-10
US20200095229A1 (en) 2020-03-26
EP3471718A1 (en) 2019-04-24
JP2019520427A (ja) 2019-07-18
US20170362207A1 (en) 2017-12-21
IL263789A (en) 2019-02-28
WO2017223155A1 (en) 2017-12-28
CA3028151A1 (en) 2017-12-28
RU2019101242A (ru) 2020-07-21
RU2019101242A3 (es) 2020-07-21
BR112018076449A2 (pt) 2019-04-09
US20210171504A1 (en) 2021-06-10
AU2017280068A1 (en) 2019-01-31
KR20190039087A (ko) 2019-04-10
EP3471718A4 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12017501825B1 (en) Bicyclic quinazolinone derivatives
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2017008280A (es) Proceso para elaborar cenicriviroc y analogos relacionados.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MX2018015697A (es) Composición de alimentación que comprende una proteasa ácida.
PH12016501613A1 (en) Pyrazines modulators of gpr6
MY188420A (en) Crystalline forms of (s)-afoxolaner
MX2018011877A (es) Proceso mejorado para la preparacion de tartrato de butorfanol.
MX2020013849A (es) Nuevos compuestos de sulfonilaminobenzamida como antihelminticos.
SG10201908248PA (en) Processes for preparing fluoroketolides
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
WO2015111085A3 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
MX2022001549A (es) Nuevas sintesis telescopicas de 2-metoximetil-p-fenilendiamina.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2018015871A (es) Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc.
MY174200A (en) Process for reducing the chlorine content of organotetraphosphites
MX2019005785A (es) Proceso para la purificacion de 1-(4-clorofenil)pirazol-3-ol.
AU2019248350A8 (en) Process for making sarecycline hydrochloride
MX2017000318A (es) Derivados del acido abscisico sustituido en 3'.
WO2020128020A3 (de) Verfahren zur herstellung von 2-alkoxy-4-amino-5-methyl-pyridinen und/oder von 2-alkoxy-4-alkylamino-5-methyl-pyridinen
MX2020010343A (es) Proceso para la purificacion de biocomposiciones complejas.